Sionna Therapeutics (NASDAQ:SION), a clinical-stage biopharma focused on developing cystic fibrosis therapies, opened well above its initial public offering price on Friday in its first trading ...
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...
The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback